Neurotrophin-4 Polyclonal Antibody, Invitrogen
Neurotrophin-4 Antibody, PA1-18393, from Invitrogen. Species Reactivity: Human, Mouse; Applications: ELISA, Immunohistochemistry, Inhibition Assays, Western Blot.
Manufacturer: Invitrogen PA118393
Neurotrophin-4 Antibody, PA1-18393, from Invitrogen. Species Reactivity: Human, Mouse; Applications: ELISA, Immunohistochemistry, Inhibition Assays, Western Blot.This gene is a member of a family of neurotrophic factors, neurotrophins, that control survival and differentiation of mammalian neurons. The expression of this gene is ubiquitous and less influenced by environmental signals. While knock-outs of other neurotrophins including nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 prove lethal during early postnatal development, NTF5-deficient mice only show minor cellular deficits and develop normally to adulthood.
Host Species: Sheep
Cross Reactivity: Human, Mouse
Immunogen: Recombinant human NT4.
Formulation: 500µg purified antibody (1mg/mL) and no preservative
Synonyms: Neurotrophin-5, NT-5, Neutrophic factor 5, Neurotrophin-4, NT-4, Neutrophic factor 4, NTF5, NTF4
Uniprot Accession: P34130, Q80VU4
Entrez GeneID: 4909, 78405
Gene Symbol: NTF4
PA1-18393 detects NT4 from human, mouse, and non-human primate samples. PA1-18393 has been successfully used in immunohistochemistry, ELISA, Western blot, and inhibition assay procedures. The PA1-18393 immunogen is recombinant human NT4. Reconstitute with 500 ul of distilled water.
|Neurotrophin-5, NT-5, Neutrophic factor 5, Neurotrophin-4, NT-4, Neutrophic factor 4, NTF5, NTF4|
|Avoid Freeze/Thaw Cycles|
|ELISA,Immunohistochemistry,Inhibition Assay,Western Blot|
|500μg purified antibody (1mg/mL) and no preservative|
|Recombinant human NT4.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok